| Multiple myeloma outlook
| [0004]
|
| Heparanase: busy at the cell surface
| [0009]
|
| Syndecan-1: a dynamic regulator of the myeloma microenvironment
| [0009]
|
| Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
| [0009]
|
| Non-anticoagulant heparins and inhibition of cancer
| [0009]
|
| Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate
| [0009]
|
| Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting
| [0009]
|
| Structure and active domains of heparin
| [0010]
|
| Structure and biological interactions of heparin and heparan sulfate
| [0010]
|
| Heparin as an anticancer therapeutic
| [0011]
|
| The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
| [0011]
|
| Glycol-splitting as a device for modulating inhibition of growth factors and heparanase inhibition by heparin and heparin derivative
| [0012]
[0013]
|
| CHEMICAL ABSTRACTS
| [0015]
|
| Merck index
| [0015]
|
| World J. Gastroenterol
| [0015]
|
| World J. Gastroenterol
| [0015]
|
| Bioorg. Med Chem
| [0015]
|
| Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide
| [0022]
|
| Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol
| [0042]
|
| Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins
| [0042]
|
| Novel regio- and stereo-selective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence
| [0043]
|
| Base-catalyzed conversion of the α-L-iduronic acid 2-sulfate unit of heparin into a unit of α-L-galacturonic acid, and related reactions
| [0043]
|
| Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity
| [0043]
|
| High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin specie to cleavage by heparanase
| [0044]
|
| Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening
| [0044]
|
| Current Protocols in Cell Biology
| [0044]
|
| The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
| [0045]
|